Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk.

@article{Urban2015PolymerfreeDC,
  title={Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk.},
  author={P. Urban and I. Meredith and A. Abizaid and S. Pocock and D. Carri{\'e} and C. Naber and J. Lipiecki and G. Richardt and A. {\'I}{\~n}iguez and P. Brunel and M. Vald{\'e}s-Ch{\'a}varri and P. Garot and S. Talwar and J. Berland and M. Abdellaoui and F. Eberli and K. Oldroyd and R. Zambahari and J. Gregson and Samantha Greene and H. Stoll and M. Morice},
  journal={The New England journal of medicine},
  year={2015},
  volume={373 21},
  pages={
          2038-47
        }
}
BACKGROUND Patients at high risk for bleeding who undergo percutaneous coronary intervention (PCI) often receive bare-metal stents followed by 1 month of dual antiplatelet therapy. We studied a polymer-free and carrier-free drug-coated stent that transfers umirolimus (also known as biolimus A9), a highly lipophilic sirolimus analogue, into the vessel wall over a period of 1 month. METHODS In a randomized, double-blind trial, we compared the drug-coated stent with a very similar bare-metal… Expand

Paper Mentions

Interventional Clinical Trial
Randomized, single-blind, single-center, non-inferiority clinical trial to compare target lesion failure (TLF) at 12 months in high bleeding risk patients who undergoing elective… Expand
ConditionsCoronary Artery Disease (CAD), High Bleeding Risk, Percutaneous Coronary Intervention (PCI)
InterventionDevice
Observational Patient Registry Clinical Trial
There are key differences today in clinical practice regarding perioperative management of post-PCI patients on DAPT undergoing NCS. Moreover, there are significant differences between… Expand
ConditionsCardiac Surgery, Percutaneous Coronary Intervention, Surgery, (+1 more)
Observational Patient Registry Clinical Trial
This prospective registry is intended to evaluate the safety and efficacy of the XIENCE Sierra stent.  
ConditionsCoronary Artery Disease, Ischemic Heart Disease
InterventionDevice
Observational Patient Registry Clinical Trial
Length of DAT (Dual Antiplatelet therapy) represents one of the most challenging choices for interventional cardiologist. Prolonged DAT reduces risk of subsequent MI (Myocardial… Expand
ConditionsCoronary Disease, Drug Eluting Stent, STEMI
InterventionDevice
2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents.
Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents
Drug-coated versus bare-metal stents for elderly patients: A predefined sub-study of the LEADERS FREE trial.
Biolimus A9 polymer-free coated stents in high bleeding risk patients undergoing complex PCI: evidence from the LEADERS FREE randomised clinical trial.
  • J. Lipiecki, P. Brunel, +9 authors P. Urban
  • Medicine
  • EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • 2018
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
...
1
2
3
...